{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:07:57Z","timestamp":1762272477540,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P#30 CA91842"],"award-info":[{"award-number":["P#30 CA91842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12032-019-1336-3","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T08:02:42Z","timestamp":1576915362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Thomas C.","family":"Westbrook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Palka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Oppelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-8227","authenticated-orcid":false,"given":"Douglas","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"issue":"1","key":"1336_CR1","first-page":"1","volume":"1","author":"J Ford","year":"2017","unstructured":"Ford J. Precision oncology: a new forum for an emerging field. JCO Precis Oncol. 2017;1(1):1\u20132.","journal-title":"JCO Precis Oncol."},{"issue":"22","key":"1336_CR2","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373\u201383.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med."},{"issue":"25","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Van de Vijver","year":"2002","unstructured":"Van de Vijver MJ, He YD, Van\u2019t veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999\u20132009.","journal-title":"N Engl J Med."},{"issue":"3","key":"1336_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA Mcarthur","year":"2014","unstructured":"Mcarthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol."},{"issue":"6046","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","volume":"333","author":"N Agrawal","year":"2011","unstructured":"Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154\u20137.","journal-title":"Science"},{"issue":"7","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","volume":"3","author":"CR Pickering","year":"2013","unstructured":"Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3(7):770\u201381.","journal-title":"Cancer Discov."},{"issue":"7","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","volume":"3","author":"VW Lui","year":"2013","unstructured":"Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761\u20139.","journal-title":"Cancer Discov."},{"issue":"6046","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","volume":"333","author":"N Stransky","year":"2011","unstructured":"Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157\u201360.","journal-title":"Science"},{"issue":"7536","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576\u201382.","journal-title":"Nature."},{"issue":"3","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","volume":"21","author":"TY Seiwert","year":"2015","unstructured":"Seiwert TY, Zuo Z, Keck MK, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632\u201341.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1172\/JCI82066","volume":"126","author":"ML Hedberg","year":"2016","unstructured":"Hedberg ML, Goh G, Chiosea SI, et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016;126(1):169\u201380.","journal-title":"J Clin Invest."},{"issue":"2","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaoncol.2016.1790","volume":"3","author":"LG Morris","year":"2017","unstructured":"Morris LG, Chandramohan R, West L, et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform. JAMA Oncol. 2017;3(2):244\u201355.","journal-title":"JAMA Oncol."},{"issue":"6","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/annonc\/mdv109","volume":"26","author":"CH Chung","year":"2015","unstructured":"Chung CH, Guthrie VB, Masica DL, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015;26(6):1216\u201323.","journal-title":"Ann Oncol."},{"issue":"12","key":"1336_CR15","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1158\/1078-0432.CCR-15-2314","volume":"22","author":"NG Chau","year":"2016","unstructured":"Chau NG, Li YY, Jo VY, et al. Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma. Clin Cancer Res. 2016;22(12):2939\u201349.","journal-title":"Clin Cancer Res."},{"key":"1336_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2016.01.003","volume":"57","author":"I Tinhofer","year":"2016","unstructured":"Tinhofer I, Budach V, Saki M, et al. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. Eur J Cancer. 2016;57:78\u201386.","journal-title":"Eur J Cancer."},{"issue":"4","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cncr.29089","volume":"121","author":"IS Hagemann","year":"2015","unstructured":"Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121(4):631\u20139.","journal-title":"Cancer"},{"key":"1336_CR18","unstructured":"National Center for Biotechnology Information. dbSNP. http:\/\/www.ncbi.nlm.nih.gov\/projects\/SNP\/Accessed 19 Jan 2019."},{"key":"1336_CR19","unstructured":"1000 Genomes. http:\/\/www.1000genomes.org. Accessed 19 Jan 2019."},{"key":"1336_CR20","unstructured":"NHLBI Exome Sequencing Project. Exome Variant Server. https:\/\/evs.gs.washington.edu\/. Accessed 19 Jan 2019."},{"key":"1336_CR21","unstructured":"Catalogue of Somatic Mutations in Cancer. http:\/\/cancer.sanger.ac.uk\/cancergenome\/projects\/cosmic\/. Accessed 19 Jan 2019."},{"issue":"2","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"10167","key":"1336_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367.","journal-title":"Lancet."},{"key":"1336_CR24","unstructured":"Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048: phase 3 study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma. Abstract presented at ESMO 2018 Congress; 2018 October 22; Munich."},{"issue":"25","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/JCO.2014.60.4165","volume":"33","author":"F Meric-bernstam","year":"2015","unstructured":"Meric-bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33(25):2753\u201362.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1336_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard C, Michiels S, Fert\u00e9 C, et al. High-Throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586\u201395.","journal-title":"Cancer Discov."},{"issue":"5","key":"1336_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751\u20138.","journal-title":"Nat Med."},{"issue":"5","key":"1336_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744\u201350.","journal-title":"Nat Med."},{"issue":"32","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","volume":"33","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817\u201325.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1336_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4143\/crt.2018.012","volume":"51","author":"SM Lim","year":"2019","unstructured":"Lim SM, Cho SH, Hwang IG, et al. Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma. Cancer Res Treat. 2019;51(1):300\u201312.","journal-title":"Cancer Res Treat."},{"issue":"13","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau C, Delord JP, Gon\u00e7alves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324\u201334.","journal-title":"Lancet Oncol."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1336-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:21:55Z","timestamp":1608423715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1336-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1336-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2019,12,21]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"12"}}